MOLBIO · Healthcare · Medical Devices
Composite scorecard: 60/100 — Quality 60
| Share price | ₹1,438.20 |
| P/B ratio | 10.6 |
| ROE | 14.0% |
| ROCE | 16.5% |
| Book value | ₹103.67 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,446 Cr | ₹164 Cr | 22.0% |
| 2025 | ₹1,020 Cr | ₹139 Cr | 26.0% |
| 2024 | ₹837 Cr | ₹84 Cr | 28.0% |
| 2023 | ₹322 Cr | ₹-1 Cr | 4.2% |
Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Tru